Cardiosphere derived cell population and methods of use
Provided herein are compositions and methods for isolating and culturing cardiac progenitor cells, and for improved transplantation.
1. A method of performing matrix-assisted cell transplantation (MACT) comprising:
contacting mammalian cells with matrix components comprising macromers and a crosslinker, wherein the crosslinker comprises a peptide that comprises CQPQGLAKC (SEQ ID NO:8); and
administering the matrix components and cells to a mammalian subject to allow for in situ crosslinking of the matrix components thereby forming a matrix within the mammalian subject.
2. The method of claim 1 , wherein the administering comprises injection.
3. The method of claim 1 , wherein the matrix is conjugated to cysteine-terminating peptides.
4. The method of claim 1 , wherein the mammalian subject has an injured heart.
5. The method of claim 4 , wherein the administering is to the injured heart.
6. The method of claim 1 , wherein the mammalian subject has an infarcted heart.
7. The method of claim 6 , wherein the administering is to the infarcted heart.
8. The method of claim 1 , wherein the mammalian subject has an ischemic heart.
9. The method of claim 8 , wherein the administering is to the ischemic heart.
10. The method of claim 1 , wherein the mammalian subject has damaged blood vessels.
11. The method of claim 10 , wherein the administering is to the site of the damaged blood vessels.
12. The method of claim 1 , wherein the mammalian subject is a human subject.
13. The method of claim 1 , wherein the cells are autologous to the subject.
14. The method of claim 1 , wherein the cells are allogeneic to the subject.
15. The method of claim 1 , wherein the matrix further comprises a growth factor.
16. The method of claim 1 , wherein the matrix and proliferated and differentiated cells further comprise a growth factor or an angiogenesis promoting factor.
17. The method of claim 10 , wherein the damaged blood vessels are due to a disease or condition selected from the group consisting of peripheral arterial disease, critical limb ischemia, chronic wounds and stroke.
18. The method of claim 1 , wherein the macromers comprise hyaluronic acid (HyA).
19. The method of claim 1 , wherein the macromers comprise acrylayted hyaluronic acid (AcHyA).
20. The method of claim 1 , wherein the cells are progenitor cells.
21. The method of claim 20 , wherein the progenitor cells are Sca-1 + CD45 − cells.
22. The method of claim 21 , wherein the progenitor cells are obtained from cardiospheres from heart tissue.
23. The method of claim 22 , wherein the heart tissue is human heart tissue.
24. The method of claim 20 , wherein the progenitor cells are cardiac progenitor cells and at least 3% of the cardiac progenitor cells express Isl1.
25. The method of claim 24 , wherein at least 10% of the cardiac progenitor cells express Isl1.
26. The method of claim 20 , wherein the progenitor cells express a cell surface marker selected from the group consisting of c-kit, CD31, CD44, CD80, CD90, CD105, CD133, CD34, Sca-1, and CD45.